San Diego, CA, Nascent Biotech Inc (NBIO: OTC) announced today that it has recently closed a non-brokered private placement round for aggregate gross proceeds of $1.2Million. Management raised funds and the use of Proceeds will be for developing antibodies used to treat cancer; including manufacturing, preparation for human clinical trials, general working capital and administration. […]
This author has yet to write their bio.Meanwhile lets just say that we are proud Nascent contributed a whooping 32 entries.
Entries by Nascent
Nascent Biotech will be a key sponsor of the 2015 edition of the Human Antibodies & Hybridomas Conference, held October 28-30, 2015, at the University of Lausanne/CHUV, in Lausanne, Switzerland. Nascent Biotech CEO Mark Glassy will serve as the program chairman of the Scientific Advisory Committee. The conference scope will include: Infectious Diseases · Autoimmunity […]
Nascent founder and chief executive officer Dr. Mark C. Glassy and chief science officer Dr. Rishab K. Gupta authored a new paper published in the Handbook of Therapeutic Antibodies, Second Edition, edited by Stefan Dübel and Janice M. Reichert (Wiley-VCH). Gupta, R. and Glassy, M. Oligoclonal and Polyclonal Antibody Preparations; in: Handbook of Therapeutic Antibodies; […]
Nascent founder and chief executive officer Dr. Mark C. Glassy and chief science officer Dr. Rishab K. Gupta have contributed a chapter to Humana Press’ new book “Human Monoclonal Antibodies: Methods and Protocols,” edited by Michael Steinitz. Glassy, M and Gupta, R. Technical and Ethical Limitations in Making Human Monoclonal Antibodies (an overview). In: Human […]
Ft Lauderdale FL July 29, 2014 – Jin-En International Group Holding Co. (“Jin-en” or “the Company”) (PINK.BB: JINZ), is pleased to announce the acquisition 100% of the outstanding shares of Nascent Biologics, a Nevada corporation (“NBI”). As part of the acquisition, the Company has agreed to change its name to Nascent Biotech Inc. and plans […]
Please click to download the 2014 Cancer Facts and Figures PDF released by the American Cancer Society. In addition, please review this document, entitled “Cancer Statistics, 2011; The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths” in PDF format.
The Journal of Bioprocess Technology has published a paper co-authored by Nascent Biologics Inc. co-founder and chief executive officer Dr. Mark C. Glassy, PhD, entitled “Use of the GPEx® System to Increase Production of Pritumumab in a CHO Cell Line.” This study highlights NBI’s relationship with Catalent, detailed here. From the paper’s abstract: Expression of […]
Somerset, NJ, November 20 2012 – Dr. Greg Bleck, R&D Platform Director-Biologics, Catalent Pharma Solutions, will participate in a panel discussion titled “How collaboration can lead to faster pipeline progression”, on Wednesday 28th November at the European Antibody Congress 2012 (27 – 28 November 2012, Starling Geneva Hotel & Conference Center, Geneva, Switzerland). Part of […]
The following article appeared at Genetic Engineering & Biotechnology News on April 17, 2012: Catalent to Use Mammalian Cell Platform to Generate Nascent’s Anticancer Antibody Nascent Biologics signed an antibody development deal with Catalent Pharma Solutions through which the latter will use its GPEx® technology to engineer a cell line expressing Nascent’s pritumumab antibody for […]
SOMERSET, NJ, and SAN DIEGO, CA – April 16, 2012 — Nascent Biologics, Inc. and Catalent Pharma Solutions today announced the signing of a product development agreement. Under the terms of the agreement, Catalent will engineer a cell line expressing Nascent’s proprietary “Pritumumab” antibody using Catalent’s GPExÒ technology, and will subsequently produce purified monoclonal antibody […]